Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder

  1. 1Division of Neurology, Kobe University Graduate School of Medicine

Abstract

Background: Neuromyelitis optica spectrum disorders (NMOSD) are severe autoimmune diseases of the central nervous system characterized by autoantibodies against aquaporin 4 (AQP4-IgG). Despite the availability of several molecular targeted therapies, biomarkers capable of predicting subsequent disability early during the acute relapse phase remain insufficient. Given that abnormalities in immune checkpoint molecules are known to be involved in autoimmunity, this study investigated whether immune checkpoint-related molecules in the cerebrospinal fluid (CSF) of acute-phase AQP4-IgG-positive NMOSD patients correlate with disability at 6 months.

Methods: Thirty-four patients with AQP4 IgG-positive NMOSD, 10 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)at disease flare, and 11 patients with idiopathic normal pressure hydrocephalus (iNPH) as control non-inflammatory neurological disease were enrolled. Bead-based multiplex assays were used to quantify levels of immune checkpoint molecules and related factors (PD-1, PD-L1, CTLA-4, TIM-3, galectin-9, LAG-3, 4-1BB, B7.2, IL-2Rα, TGF-β1, FasL) in CSF. These molecules were measured in the soluble fraction. Disease severity at 6 months was classified as mild (EDSS < 6) or severe (EDSS ≥ 6). ROC analysis was performed to evaluate prognostic performance.

Results: Twenty-six cases of NMOSD showed mild disability, and 8 cases showed severe disability. All cases of MOGAD showed mild disability. Compared to the mild group, the severe group had higher age, a higher male ratio, and higher cerebrospinal fluid protein levels (p=0.004, p=0.017, p<0.001, respectively). Cerebrospinal fluid levels of TIM-3, galectin-9, and IL-2Rα were significantly higher in the severe group (p=0.011, p=0.008, p=0.006, respectively), with area under the ROC curve values of 0.89, 0.88, and 0.80, respectively.

Conclusion: In AQP4-IgG-positive NMOSD patients, elevated levels of TIM-3, galectin-9, and IL-2Rα in CSF during the acute attack phase correlate with worsening disability severity at 6 months. These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.

Related

  1. Higher observed 12-month relapse-free survival with satralizumab than with rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a multicenter retrospective cohort study
    Xiao Lin, Jicheng Zhang, Lei Chen +16
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  2. Galectin-1 deficiency attenuates imiquimod-induced psoriasiform skin inflammation and is associated with reduced macrophage recruitment
    Shiu-Ju Yang, Shih-Yao Chen, Chia-Hsin Hou +6
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMCCrossref
  3. Cerebrospinal fluid C-reactive protein to diagnose healthcare-associated meningitis after neurosurgical procedures: An exploratory retrospective diagnostic accuracy study.
    M Foppen, I O Kommers, S E Olie +3
    Brain & spinePeer-reviewedCC BYFull textMicrobiologyEurope PMC
  4. Epidemiology, clinical outcomes, and factors associated with mortality among cerebrospinal meningitis cases in the Upper West Region of Ghana: an eight-year surveillance study.
    Abdul-Wahab Chiemina Bakariwie, Andrew Mpagwuni Ziblim, Abdul-Hanan Saani Inusah +2
    BMC infectious diseasesPeer-reviewedCC BYFull textMicrobiologyEurope PMCDOAJ
  5. Why repair fails in AQP4-IgG-positive neuromyelitis optica spectrum disease: an astrocyte-centered framework for remyelination and neuroaxonal preservation
    Wenjing Luo, Ni Peng, Siqian Wei +3
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
BibTeX
@article{nishii2026soluble,
  title = {{Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder}},
  author = {Shota Nishii and Ritsu Akatani and Kyoka Shiroma and Ryosuke Takeda and Asato Tsuji and Kimitaka Katanazaka and Shusuke Koto and Norio Chihara},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1923404},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1923404/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder
AU  - Shota Nishii
AU  - Ritsu Akatani
AU  - Kyoka Shiroma
AU  - Ryosuke Takeda
AU  - Asato Tsuji
AU  - Kimitaka Katanazaka
AU  - Shusuke Koto
AU  - Norio Chihara
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1923404
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1923404/full
AB  - Background: Neuromyelitis optica spectrum disorders (NMOSD) are severe autoimmune diseases of the central nervous system characterized by autoantibodies against aquaporin 4 (AQP4-IgG). Despite the availability of several molecular targeted therapies, biomarkers capable of predicting subsequent disability early during the acute relapse phase remain insufficient. Given that abnormalities in immune checkpoint molecules are known to be involved in autoimmunity, this study investigated whether immune checkpoint-related molecules in the cerebrospinal fluid (CSF) of acute-phase AQP4-IgG-positive NMOSD patients correlate with disability at 6 months.  Methods: Thirty-four patients with AQP4 IgG-positive NMOSD, 10 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)at disease flare, and 11 patients with idiopathic normal pressure hydrocephalus (iNPH) as control non-inflammatory neurological disease were enrolled. Bead-based multiplex assays were used to quantify levels of immune checkpoint molecules and related factors (PD-1, PD-L1, CTLA-4, TIM-3, galectin-9, LAG-3, 4-1BB, B7.2, IL-2Rα, TGF-β1, FasL) in CSF. These molecules were measured in the soluble fraction. Disease severity at 6 months was classified as mild (EDSS < 6) or severe (EDSS ≥ 6). ROC analysis was performed to evaluate prognostic performance.  Results: Twenty-six cases of NMOSD showed mild disability, and 8 cases showed severe disability. All cases of MOGAD showed mild disability. Compared to the mild group, the severe group had higher age, a higher male ratio, and higher cerebrospinal fluid protein levels (p=0.004, p=0.017, p<0.001, respectively). Cerebrospinal fluid levels of TIM-3, galectin-9, and IL-2Rα were significantly higher in the severe group (p=0.011, p=0.008, p=0.006, respectively), with area under the ROC curve values of 0.89, 0.88, and 0.80, respectively.  Conclusion: In AQP4-IgG-positive NMOSD patients, elevated levels of TIM-3, galectin-9, and IL-2Rα in CSF during the acute attack phase correlate with worsening disability severity at 6 months. These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
SN  - 1664-3224
ER  -